Along with Contrafect, I'm also invested in another company called Armata Pharmaceuticals (ARMP) that is also working on treatments for antibiotic resistant bacteria. The difference, as I understand it, is that ARMP is using a class of viruses called phages, that commonly occur naturally in our environment and attack bacteria, as an injectable treatment. Contrafect is also researching phages, but instead of injecting the virus into patients, they are developing drugs based how these viruses destroy bacteria. While Armata may have an edge in flexibility of finding different viruses that can be used to attack different bacterial diseases, Patients and doctors may find using a drug treatment preferable to injecting live virus into a human. I think both approaches could be viable. Contrafect seems to be a step ahead on clinical trials...
News 
Market Data 
Discover 
AI
